Qorvo

Phase A — Understand the business

Company Overview

Qorvo is a radio-frequency (RF) and analog/mixed-signal semiconductor maker formed in Jan-2015 from the merger of RF Micro Devices and TriQuint. It designs, makes (in part) and sells components that get a signal on and off the air: power amplifiers, filters (BAW/SAW), switches, tuners, LNAs, envelope-tracking PMICs and integrated front-end modules. FY2026 (year ended 28 Mar 2026) revenue was $3,678.5M, down 1.1% YoY; net income $339.0M; diluted EPS $3.62.

Three reportable segments:

• ACG (Advanced Cellular Group) — RF front-ends for smartphones/wearables/tablets. The cash cow: $2,551.2M FY26 revenue (69% of total), segment operating income $667.4M.
• HPA (High Performance Analog) — defense & aerospace, base-station/infrastructure, broadband (DOCSIS 4.0), industrial power management. The growth/quality engine: $705.7M (19%), op income $189.4M, growing.
• CSG (Connectivity & Sensors Group) — UWB, Matter, BLE, Wi-Fi, IoT connectivity. The problem child: $421.7M (11%), operating loss $(42.3)M in FY26 (a narrowing loss).

Customer structure is the whole story. Apple is ~50% of total revenue in FY26 (47% FY25, 46% FY24 — rising), sold through contract manufacturers; Samsung ~10%. Top three receivable balances = 58% of gross AR. Contracts are largely design-win/PO-based with rebate structures — not take-or-pay, not recurring; revenue must be re-won every product cycle. This concentration is precisely why the company is selling itself.

Competitors: ACG vs. Broadcom, Qualcomm, Murata, Skyworks (its acquirer), Maxscend, Vanchip; HPA vs. Analog Devices, MACOM, Texas Instruments, Renesas, Monolithic Power, Mini-Circuits; CSG vs. Broadcom, NXP, Qualcomm, Nordic, Silicon Labs.

Supply Chain

Qorvo runs a hybrid fab-lite / own-fab model — it internally produces only the most differentiated pieces and outsources the rest.

Upstream → Qorvo → end customer:

• Own wafer fabs: Oregon and Texas (GaAs, GaN, BAW, SAW process technologies are the crown jewels).
• Own assembly & test: Germany and Texas. The footprint is being aggressively consolidated: closed/sold the North Carolina SAW fab (net proceeds $36.8M, FY26 Q4; SAW production moving to Texas); sold China assembly/test (Beijing + Dezhou) to Luxshare (FY25, with an inventory-repurchase supply agreement — note the $118.5M "inventory subject to repurchase" liability); divested Costa Rica assembly/test.
• Sourced inputs: GaAs substrates, SOI/SiGe/CMOS wafers from external foundries; "large number of sources" with qualified second sources.
• Downstream: components → contract manufacturers (Foxconn et al. for Apple) → Apple (~50%), Samsung (~10%); plus defense primes / the U.S. government (HPA), base-station OEMs, automotive Tier-1s.

Chokepoints: (1) the Apple socket is the single dominant dependency — one customer, re-competed annually, sourced through CMs Qorvo doesn't control; (2) own BAW/SAW filter fabs are the differentiated asset and the antitrust pinch-point in the Skyworks deal (BAW overlap); (3) Luxshare supply-agreement entanglement post-China-divestiture.

Competitive Advantages (moats)

Real but narrow, and shrinking in mobile.

• Process-technology IP / own filters (durable): BAW and SAW filter expertise plus GaN/GaAs fabs are genuinely hard to replicate and are why Skyworks is paying up — filters are the scarce content in 5G/Wi-Fi 7 front-ends. This is the strongest moat.
• Design-win switching costs (moderate): Once a Qorvo module is qualified into an iPhone or flagship Android RF board, it's sticky for that generation — but only that generation. Re-designed every cycle.
• Defense relationships (durable, small): HPA's direct U.S.-government and defense-prime relationships ("trusted partner," GaN for radar/EW, Golden Dome, LEO SATCOM) are sticky and ITAR-moated. This is the highest-quality revenue but only ~half of a 19%-of-revenue segment.
• Bargaining power — weak vs. customers, OK vs. suppliers: Apple at 50% of revenue holds overwhelming pricing leverage; Qorvo is a price-taker into its largest socket. That asymmetry — Qorvo needs Apple far more than Apple needs Qorvo — is the core structural flaw and the reason the standalone multiple is depressed.

Net: a moat strong enough to be worth acquiring for its filters and defense IP, too weak to defend mobile margins or win the customer-concentration argument alone.

Segments

Three-year segment table — all figures $M:

Geography (by customer HQ): US $2,315.8M (63%), China $474.9M (13%, down from $726.8M in FY24), Other Asia $431.9M, Taiwan $357.7M, Europe $98.3M. The China decline (−35% over two years) is partly the deliberate mass-market-Android exit and partly share loss to Maxscend/Vanchip — and it doubles as the antitrust de-risking argument (less Chinese overlap to object to).

The deliberate FY26 thesis, in management's words: "reduce exposure to lower margin, mass-market Android smartphones" + "favorable business mix within HPA" drove gross margin to 45.9% (FY26) from 41.3% (FY25). They are shrinking revenue on purpose to fix margins — a textbook pre-sale grooming move.

---

Phase B — Measure performance

Earnings Result (latest print + full-year)

Most recent quarter — Q3 FY2026, ended 27 Dec 2025:

• Revenue $993.0M (+8.4% YoY vs. $916.3M) — beat, driven by ACG +$55.7M (flagship content), HPA +$19.2M (base stations, DOCSIS 4.0, D&A), CSG +$1.7M.
• Gross margin 46.7% vs. 42.7% YoY — the margin-mix story working.
• Diluted EPS $1.75 (GAAP) vs. $0.43 YoY; net income $164.1M.
• Effective tax rate 13.6% for the quarter.
• Notable items: merger-related costs $14.7M; a $19.2M gain on the MEMS divestiture; start-up costs $3.9M for the NC→TX SAW transfer; a $9.8M restructuring charge.

Full-year FY2026: revenue $3,678.5M (−1.1%); gross profit $1,688.1M (GM 45.9%, up 460bps); operating income $411.4M (vs. $95.5M FY25 — FY25 was depressed by $192.6M of impairments); net income $339.0M; diluted EPS $3.62. Operating cash flow $808.6M (vs. $622.2M) — strong, helped by a $86.6M inventory drawdown.

Balance sheet (28 Mar 2026): cash $1,219.0M; total debt $1,549.2M (4.375% notes due 2029 $850M; 3.375% notes due 2031 $700M) → net debt ~$330M; no revolver drawn ($325M available); inventory $553.7M (down from $641.0M — healthy); goodwill $2,353.2M; total equity $3,344.3M. Net debt/EBITDA well under 1x — a clean, lightly-levered balance sheet.

Capital returns: repurchased 6.6M shares for $536.7M in FY26 (4.0M/$358.8M FY25); $416.2M remained authorized; buybacks were suspended on signing the Skyworks deal, then resumed in Q4 FY26 within merger-agreement limits. No dividend.

Market reaction / what's priced: QRVO trades ~$93.87 (30 Jun 2026, intraday), well above any standalone DCF and right inside the deal band — confirming the tape is trading the arb, not the fundamentals. Next print: ~28 Jul 2026.

Earnings Calls (sentiment trend)

No transcripts on the research-layer shelf (transcripts/ empty); sentiment read from MD&A language across the FY26 10-QForm 10-QThe quarterly version of the annual report. Lighter, and not audited. and 10-KForm 10-KA company’s audited annual report to the US regulator. The most complete thing it publishes. plus deal communications:

• Tone shift over FY26: from "navigating a soft mobile/Android market" (early FY26) → "margin discipline is working, mix-shift to HPA + flagship" (Q3) → "all roads lead to the Skyworks close" (post-Oct-2025). Once the deal was signed, the standalone-operating narrative effectively went quiet — management commentary now centers on integration, $500M+ synergy targets, and regulatory progress.
• Recurring phrases: "narrow focus on higher-margin portfolio," "reduce exposure to mass-market Android," "favorable business mix," "defense and aerospace content gains," "DOCSIS 4.0."
• Things they stopped saying: standalone long-term revenue-growth targets, CSG turnaround timelines, capital-return guidance — all subsumed by the merger. The absence of forward standalone guidance is itself the signal: they are running to a finish line, not a strategy.

Comps

Peer table — RF/analog/mixed-signal. Multiples are with source/date; where I cannot source a clean figure I mark it n/a. Do not read these as precise — semis multiples swing daily and several sources disagreed (conflicts flagged).

Read: Standalone, QRVO (13.6x fwd P/E, 10.6x EV/EBITDA) and SWKS (14.7x, 8.9x) are the cheap, ex-growth pure-plays — the market caps them like declining handset suppliers, not growth semis. MACOM's 58.7x P/E / 117x EV/EBITDA is the market paying up for diversified RF growth away from mobile — the precise multiple QRVO/SWKS can't command alone, and the strategic logic for combining. The comp set confirms the deal's premise: scale + diversification is the only re-rating path.

Stock-Price Catalysts (>5% moves, ~5yr)

Pattern from price history:

• Apr 2021 peak (~$200+ split-adj basis) → 2022 crash −60.7% during the inflation shock + smartphone/Android inventory glut. The stock's beta to the handset cycle and to Apple build rates is the dominant historical driver.
• 2022–2023: repeated >5% moves on Android-inventory-correction updates and Apple build-rate news; trough GM ~41% guided.
• Late-2023 recovery: +70% sequential revenue quarter on earlier Apple shipments + China-Android restock.
• 27 Oct 2025 — the regime change: Skyworks-merger announcement; QRVO jumps and decouples from fundamentals — it now trades on deal odds.
• 22 May 2026: "mobile-chip trade" rally — QRVO +7%, SWKS +9%, QCOM +12% — but for QRVO this is largely SWKS-stock beta flowing through the 0.960 exchange ratio, not a standalone re-rate.
• 5 Feb 2026 (FTC Second Request) and SAMR Phase-II headlines: the new catalyst axis — every regulatory data point now moves the spread.

What the market reacts to: historically Apple build rates + Android inventory + GM trajectory; now, regulatory-approval probability and the SWKS share price. The fundamental catalysts have been almost entirely displaced by deal catalysts.

---

Phase C — Judge people & books

Management

• CEO Robert (Bob) Bruggeworth — CEO since the 2015 RFMD/TriQuint combination (CEO of RFMD from 2003); ~12-year tenure, deep RF operator. Owns 0.34% ($25M); FY26 comp ~$13.5M, 92% equity-linked. Recent insider activity: sales only (4 sales, ~58k shares) — normal 10b5-1Rule 10b5-1 planA schedule an insider sets in advance saying when their shares will be sold, so the sales cannot be timed on private news. A sale made OUTSIDE such a plan is a live decision, which is why it carries more information. selling, and he adopted a new 10b5-1 plan 25 Feb 2026.
• Track record: navigated the brutal 2022–23 Android downcycle, then executed a credible margin-repair (GM 41%→46%) by exiting low-margin mass-market Android, divesting non-core units (SiC, MEMS, China/Costa Rica/NC assets), and concentrating on HPA + flagship. That's competent portfolio surgery.
• Capital allocation — mixed: disciplined buybacks at depressed prices ($1.3B over 3yr) and aggressive footprint rationalization are good; but the TriQuint-era goodwill ($2.35B, with $1.08B cumulative impairments already taken) and repeated CSG impairments ($221.4M FY24, $36.5M FY26) say prior M&A and the IoT/CSG bet destroyed value. ROE has been volatile (FY24 net loss; FY26 ROE ~10%).
• The defining capital-allocation act is the sale itself. Agreeing to sell to Skyworks — an all-but-merger-of-equals at 37/63 — is management conceding that standalone, the customer-concentration + ex-growth-mobile problem is unsolvable, and that scale/diversification + $500M synergies is the better path for holders. That is an honest, shareholder-aligned read of a hard position. Archetype: professional operator/steward, not founder — appropriate for an end-of-cycle consolidation.

Forensic Red Flags

Ground: financials + filings; every figure labeled.

• Customer concentration (the #1 flag): Apple ~50%, top-3 AR = 58%. Not accounting fraud — but a single-point-of-failure that makes every other line fragile.
• Goodwill still large vs. equity: $2,353M goodwill on $3,344M equity (70%). $1,084M already impaired cumulatively; a fresh $36.5M CSG goodwill + $45.9M intangible impairment in Mar-2026. Watch CSG for further writedowns — but the Skyworks close likely moots this.
• "Inventory subject to repurchase" — non-standard: $118.5M liability tied to the Luxshare supply agreement; inventory legally Luxshare's but kept on Qorvo's balance sheet under ASC 606/330, with financing cost in interest expense. Legitimate but a quirk that flatters neither cash flow nor clarity; understand it before trusting working-capital trends.
• Non-GAAP vs. GAAP gap: $136.1M SBC + $85.0M intangible amortization + $50.7M restructuring + $23.5M merger costs are excluded from segment operating income. SBC at ~3.7% of revenue is moderate for semis; the adjustments are well-disclosed and reconcile cleanly. No evidence of aggressive non-GAAP flattering beyond industry norm.
• Cash flow vs. earnings: OCF $808.6M comfortably exceeds net income $339.0M (non-cash impairments/D&A/SBC); receivables flat, inventory down — no divergence red flag. Clean.
• Tax: FY26 ETR ~14.9%; uses foreign tax-holiday regimes (Singapore, China, Germany) — a forward risk if holidays lapse, disclosed.

Regulatory findings (required):

• SEC Litigation Releases / AAERs: None. EDGAR EFTS search (LR + AAER) returned 0 findings for Qorvo, 2021-06-30 → 2026-06-30.
• Item 3 / Note 11 Legal Matters (10-K): only ordinary-course proceedings; management states no individually or aggregate material adverse effect; range of reasonably-possible losses in excess of accruals is not material.
• Non-SEC enforcement: Web search surfaced no FTC/DOJ/FDA fines or consent decrees against Qorvo. The only regulatory event of note is the HSR Second Request (5 Feb 2026) and the China SAMR Phase-II review — these are merger-clearance processes, not enforcement actions against the company.
• Conclusion: No material regulatory or legal findings against the company itself — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3/Note 11 as of 2026-06-30. The live regulatory question is purely deal-approval, addressed in Lenses 12–13.

---

Phase D — Project & stress-test

Forward Projection (standalone — the broken-deal anchor)

This is a deliberate two-track projection. Because the price is a deal-spread, the relevant numbers are (a) the arb payoff and (b) the standalone EPS that sets the broken-deal floor. No our model logged (watchlist/unattended; standalone EPS is not a committed view given the deal overhang).

(a) The merger-arb payoff:

• Deal consideration = $32.50 cash + 0.960 × SWKS.
• At SWKS $72.74: 0.960 × 72.74 = $69.83 + $32.50 = $102.33 implied deal value.
• QRVO at $93.87 → gross spread $8.46 = 9.0%. (At the alt-quoted $95.85, spread ≈ $6.48 = 6.8%.)
• Annualized to an "early CY2027" (~Feb-2027, ~8mo) close: 9.0% × (12/8) ≈ ~13.5%; to a late-2026 (~5mo) close: 9.0% × (12/5) ≈ ~21.6%.
• The spread IS the forecast. A ~9% gross / ~13–22% annualized return is the market pricing meaningful deal risk — wider than a clean strategic deal, consistent with the FTC Second Request + SAMR Phase-II overhang on two close RFFE competitors.

(b) Standalone EPS path (the broken-deal floor):

• Base — FY27 GAAP EPS ~$4.00–4.40. FY26 actual $3.62; margin-mix tailwind continues (GM ~46–47%), revenue roughly flat-to-+low-single-digit, HPA growth offsetting mobile/CSG softness, buyback shrinks share count ~2–3%.
• Bull — ~$4.75: HPA/defense + DOCSIS 4.0 accelerate, Apple content per-phone rises, GM pushes 48%.
• Bear — ~$3.00: Apple build cut or socket share loss, CSG writedown, China erosion — the standalone downside.
• Broken-deal price ≈ 14–16x standalone ≈ high-$50s to high-$60s (where it traded pre-announcement), i.e. ~25–35% downside from ~$94 if the deal breaks. That asymmetry — ~9% up to deal, ~30% down on break — is the entire risk/reward.

Bull vs Bear

Bull case (own the spread / believe the deal closes). A ~9% gross / ~13–22% annualized arb on a deal that both shareholder bases have already approved, with a clean strategic rationale (combined ~$7.7B revenue RFFE/analog leader, $500M+ cost synergies, customer-concentration diluted across the combined book), a lightly-levered target ($330M net debt, $1.2B cash), no company-level legal overhang, and a $100M reverse-termination fee partially cushioning antitrust-fail downside. China and the US both have de-risking arguments: QRVO and SWKS have each lost share to Qualcomm and Chinese players, weakening any "merger creates dominance" objection. Sources peg ~85% US and ~75% China clearance odds.

Bear case (the deal breaks or drags). Two of the three close Western RFFE competitors combining is a textbook horizontal merger; the FTC Second Request and SAMR Phase-II bundling/BAW concerns are real, and the most likely "fix" — divesting Skyworks' BAW filter business — could erode the synergy math or be rejected. A break sends QRVO to a high-$50s–$60s standalone (~30% down). Even a delay from late-2026 to the Oct-2027 outside date crushes the annualized return and ties up capital. And the standalone business underneath is structurally challenged: 50% Apple, ex-growth mobile, a loss-making CSG, share loss in China.

Pre-mortem (18 months out, thesis broke): The FTC sued to block (close RFFE competitors, BAW overlap, the agency's own former bureau director flagged client concerns) OR SAMR slow-walked past the outside date with unacceptable behavioral remedies. The deal terminated; Skyworks paid the $100M reverse fee; QRVO re-rated to ~$60 on standalone fundamentals into a soft iPhone cycle. Arb holders lost ~30%.

Are multiples too high? Standalone, no — 13.6x fwd P/E is cheap. But you're not paying the standalone multiple; you're paying ~$94 for a $102 deal that might not happen. The "multiple" that matters is the implied probability of close (~85–90% baked into the ~9% spread).

Contrarian view (what the market may be missing): The spread may be too wide if you believe the share-loss/de-concentration argument genuinely neutralizes the antitrust case — i.e., the market is over-weighting the "two of three competitors" optics and under-weighting that both are losing players consolidating to survive against Qualcomm. If clearance comes by late-2026, the realized annualized return (~20%+) would have been a fat, low-correlation arb.

Devil's Advocate (short-seller)

Short the broken-deal scenario, or fade the "easy close" complacency.

• The merge-the-losers story cuts both ways for antitrust. The FTC under current posture has shown willingness to challenge semis consolidation; a Second Request plus a former bureau director publicly noting customer concerns is exactly how a suit starts. "We're both losing share" is a defense, not a guarantee.
• BAW is the kill-shot. Both own BAW filter capability — the scarcest RFFE content. A forced BAW divestiture either guts the synergy thesis (so SWKS walks or renegotiates) or the regulators reject the remedy. Either way the spread blows out.
• Standalone, this is a melting ice cube at 50% Apple. If the deal dies, you own a single-customer-dependent, ex-growth handset supplier with a chronic loss-making CSG segment, $2.35B of acquisition goodwill (already impaired $1.08B), and Chinese competitors (Maxscend, Vanchip) taking the mass-market it's abandoning. The high-$50s isn't a floor — a hard Apple cycle could take it lower.
• Exchange-ratio risk: 0.960 of the consideration is SWKS stock — if Skyworks' own (also-challenged, ex-growth) shares fall, the deal value falls with them; the arbitrageur is long SWKS beta whether they want to be or not.
• What must hold for ~$94: (1) FTC clears (with at most a sub-$100M-revenue carve-out per the merger agreement's divestiture cap); (2) SAMR clears in China; (3) SWKS holds ~$70+; (4) close by ~early-2027. Break any one and the math inverts.
• Permanent-impairment scenario: Deal blocked → standalone re-rate to ~$60 → into a 2027 iPhone unit decline + accelerated Chinese share loss in mid-tier → a $45–50 stock. Plausible? Low-but-not-trivial; the antitrust path is the live risk.

Management Questions (ordered by information value)

1. What is your current best estimate of the probability and timing of FTC clearance, and what specific divestitures (BAW? other) have you offered or modeled?
2. On China SAMR Phase II — what behavioral or structural remedies has SAMR signaled, and what is your drop-dead date before you'd consider it a failed condition?
3. If the deal terminates, what is the standalone capital-return and strategic plan on day one — and would you immediately restart buybacks at the depressed price?
4. Quantify the $500M+ synergy target: how much is COGS/fab consolidation vs. opex, and how much is at risk under a BAW divestiture remedy?
5. Apple is now ~50% of revenue and rising — what is the dollar-content trajectory per flagship iPhone over the next 3 cycles, and where do you lose or gain sockets?
6. What is the realistic timeline and margin path to CSG profitability standalone, and at what point do you exit IoT connectivity entirely?
7. How much of HPA's defense/aerospace growth is funded program backlog (Golden Dome, radar upgrades, LEO SATCOM) vs. design-win pipeline, and what's the book-to-billBook-to-billNew orders divided by orders filled. Above 1 means the backlog is growing; below 1 means the company is working through it faster than it is replacing it.?
8. What share have you ceded to Maxscend and Vanchip in mass-market Android, and is that permanent?
9. Post-close, how does the combined entity reduce Apple concentration in practice rather than just on paper?
10. What is the GM ceiling for the standalone business at the current portfolio mix, and what gets you there?
11. How exposed is the deal value to SWKS's own share price, and have you considered a collar?
12. What is your contingency if a 2027 smartphone-unit downturn coincides with a deal delay?
13. How much further footprint consolidation (fabs, assembly/test) is planned, and what's the one-time cost vs. run-rate savings?
14. What is the status of the Luxshare inventory-repurchase obligation, and when does it unwind?
15. Are foreign tax-holiday regimes (Singapore, Germany, China) at risk of lapsing, and what would that do to the effective tax rate?

---